Astellas, Seattle Genetics Break Ground With US ADC Approval
Earlier-Stage Combo Also Shows Big Promise
Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.
You may also be interested in...
Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.